South Korea’s Hyundai ADM unveils oral chemotherapy drug
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.
Samsung Biologics has announced a $1.24 billion manufacturing deal with an unnamed Asian pharmaceutical company.
HQ Team September 25, 2023: Eisai Co., and Biogen Inc., announced that their drug to treat Alzheimer’s disease and cognitive impairment has been.
HQ Team July 25, 2023: The Middle East Respiratory Syndrome Coronavirus has killed 12 people in the UAE and infected 94 others from.
HQ Team June 8, 2023: Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority.
Biovac, a South Africa-based biotechnology company, has signed a technology transfer agreement with a South Korean institute to make an oral cholera vaccine.